Agios releases first AG-120 dose expansion cohort data
Agios Pharmaceuticals recently presented the first data from its Phase 1 AG-120 study dose expansion cohorts at the Society for Neuro-Oncology annual meeting. Read More »
Agios Pharmaceuticals recently presented the first data from its Phase 1 AG-120 study dose expansion cohorts at the Society for Neuro-Oncology annual meeting. Read More »
Alnylam Pharmaceuticals published results from its Phase 1 clinical trial involving inclisiran in The New England Journal of Medicine. Read More »
Janssen-Cilag International NV's STELARA has been approved by the European Commission to treat adult patients who have moderate-to-severe Crohn’s disease and did not respond well to or are immune to conventional therapy or a tumor necrosis factor alpha antagonist. Read More »
Momenta Pharmaceuticals and Mylan N.V.'s first patient in its Phase 1 study of M834 has been dosed. The trial will evaluate M834's pharmacokinetics, safety and immunogenicity. Read More »
Vertex Pharmaceuticals has released an update on the development of its upcoming Phase 3 program involving its investigational compound VX-661. Read More »
Sunovion Pharmaceuticals' acquisition of Cynapsus Therapeutics has been finalized through Sunovion's subsidiary Sunovion CNS Development Canada. Read More »
Tetraphase Pharmceuticals has placed its first patient in its Phase 3 IGNITE4 clinical study involving intravenous eravacycline has been dosed with the medication. Read More »
Catabasis Pharmaceuticals' Andrew Nichols has been named the company’s new chief scientific officer and Angelika Fretzen has been named senior vice president of product development. Read More »
Epizyme Inc. has agreed to a partnership with Foundation Medicine to identify and enroll support patients for the upcoming Phase 2 trial of tazemetostat on patients who have non-Hodgkin lymphoma. Read More »
Abbott announced this week that its FreeStyle Libre Pro system, a groundbreaking continuous glucose monitoring (CGM) system designed for patients with diabetes, has been approved by the U.S. Food and Drug Administration (FDA).re Read More »
Tarix Orphan LLC recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to TXA127, the company’s prospective treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. Read More »
Johnson & Johnson recently made a five-year commitment to aid the United Nations Sustainable Development Goals in its mission to see the improvement of the health and well-being of people worldwide. Read More »
Akcea Therapeutics, an Ionis Pharmaceuticals subsidiary, recently reported that significant results from two clinical studies of INOIS-APO(a) and IONIS-APO(a)-L have been published in The Lancet. Read More »
Aegerion Pharmaceuticals Inc. has appointed Remi A. Menes as its Chief Commercial Officer (CCO) effective immediately. Read More »
Gate Pharmaceuticals Inc. today announced that its subsidiary, Jade Therapeutics, has received a second year of funding from the U.S. Army Medical Research and Material Command (USAMRMC) for a total of $448,185 to develop proprietary thiolated hyaluronic acid for use as an ocular bandage film. Read More »
Collegium Pharmaceuticals Inc. announced that an independent review of Xtampza ER will be published in The Journal of the American Medical Association (JAMA). Read More »
Program designs synthetic oligonucleotide-based drug candidates for cancer and rare disease treatments. Read More »
A majority of health care plans and programs with a drug exclusion policy have been successful, reducing costs and not negatively impacting patient care, concludes a new study published in The American Journal of Managed Care. Read More »
In the wake of a large jury verdict against Johnson & Johnson, the health products industry is closely watching a debate over expert witness standard legislation in Missouri. Read More »
Juniper Pharmaceuticals Inc. announced last week its Phase IIb clinical trial for COL-1077, which was recently completed, did not meet either its primary or secondary goals. Read More »